You are here

Article Text

Article menu
Download PDFPDF
Editorial
Investing in COPD: biologics or smoking cessation and pulmonary rehabilitation?
  1. Jo Congleton
  1. Brighton and Sussex University Hospitals NHS Trust, Brighton, UK
  1. Correspondence to Dr Jo Congleton, Brighton and Sussex University Hospitals NHS Trust, Brighton, UK; jo.congleton{at}nhs.net

https://doi.org/10.1136/dtb.2024.000005

Statistics from Altmetric.com

    Request Permissions

    If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

    Anti-eosinophil and anti-IgE monoclonal antibodies (biologics) now have an established place in managing poorly controlled eosinophilic asthma—though there remains a need to improve access for eligible patients.1 In July 2023, the New England Journal of Medicine published the results of a randomised placebo-controlled trial of the monoclonal antibody dupilumab in 939 people with chronic obstructive pulmonary disease (COPD), a blood eosinophil count of 0.3 x 109/L, a high exacerbation rate (mean rate 2.3/year) and who were using triple inhaled therapy.2 The trial reported a lower rate of moderate or severe exacerbations in the dupilumab group (0.78/year vs 1.1/year), most of which was due to a reduction in moderate exacerbations. Dupilumab is not yet licensed in the UK for COPD, but given the large number of people with COPD and the negative …

    View Full Text

    Footnotes

    • Competing interests None declared. Refer to the online supplementary files to view the ICMJE form(s).

    • Provenance and peer review Commissioned; externally peer reviewed.

    • Supplemental material This content has been supplied by the author(s). It has not been vetted by BMJ Publishing Group Limited (BMJ) and may not have been peer-reviewed. Any opinions or recommendations discussed are solely those of the author(s) and are not endorsed by BMJ. BMJ disclaims all liability and responsibility arising from any reliance placed on the content. Where the content includes any translated material, BMJ does not warrant the accuracy and reliability of the translations (including but not limited to local regulations, clinical guidelines, terminology, drug names and drug dosages), and is not responsible for any error and/or omissions arising from translation and adaptation or otherwise.

    Linked Articles